CLSD - Clearside Biomedical, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.2700
+0.1200 (+10.43%)
At close: 04:00PM EDT
1.3200 +0.05 (+3.94%)
After hours: 07:15PM EDT
Stock chart is not supported by your current browser
Previous Close1.1500
Open1.1800
Bid1.2300 x 800
Ask1.5300 x 3200
Day's Range1.1799 - 1.2900
52 Week Range0.9000 - 1.8550
Volume165,338
Avg. Volume179,106
Market Cap78.316M
Beta (5Y Monthly)2.08
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

    - U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that enrollment has opened in ODYSSEY, its Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) using suprachoro

  • GlobeNewswire

    Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update

    - Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected to Open Enrollment in Q2 2023 - - Positive Safety Data, Duration and Biologic Effect of CLS-AX Over 6 Months in OASIS Phase 1/2a Extension Study Highlighted in Presentations at Recent Medical Meetings - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., May 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the

  • GlobeNewswire

    Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference

    ALPHARETTA, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer will participate in a Fireside Chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023, at 9:30 a.m. ET. A link to the live and archived webcast may be accessed

  • GlobeNewswire

    Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

    ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corporate up

  • GlobeNewswire

    Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

    - Suprachoroidal delivery of small molecule suspensions demonstrated targeted, compartmentalized and durable drug delivery -ALPHARETTA, Ga., April 27, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that several key poster presentations were delivered on the Company’s suprachoroidal injection delivery platform at The Association

  • GlobeNewswire

    Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

    ALPHARETTA, Ga., April 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple poster presentations will be given on the Company’s suprachoroidal injection delivery platform at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting taking place April 23-27, 2023, in New Orleans, LA. Title:

  • GlobeNewswire

    Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

    - Multiple U.S. Clinical Sites to Begin Enrolling ODYSSEY Participants This Quarter - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today plans for ODYSSEY, a randomized, double-masked, parallel-group, active-controlled, multi-center Phase 2b clinical trial o

  • GlobeNewswire

    Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

    ALPHARETTA, Ga., April 12, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19, 2023, at 1:30 p.m. ET. A link to the live and archived webcas

  • GlobeNewswire

    Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians

    ALPHARETTA, Ga., April 05, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced the appointment of Arshad M. Khanani, M.D., M.A, F.A.S.R.S and Lejla Vajzovic, M.D., F.A.S.R.S to its Scientific Advisory Board (SAB). Clearside’s SAB is comprised of industry leading retinal physicians who provide medical and scientific expertise and inpu

  • GlobeNewswire

    Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

    - Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety Data, Durability, and Biologic Effect Over 6 Months - - Continued Growth in Retinal Specialists Trained in Suprachoroidal Space (SCS®) Injection Procedure Using FDA-Approved XIPERE® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 09, 2023 (GLOBE NEWSWI

  • GlobeNewswire

    Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

    ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2022 financial results will be reported on Thursday, March 9, 2023 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provi

  • GlobeNewswire

    Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

    - CLS-AX OASIS Results Show Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - SCS Microinjector® Featured in Favorable Data Presentations Related to Multiple Therapies in Clinical Development – ALPHARETTA, Ga., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announ

  • GlobeNewswire

    Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

    ALPHARETTA, Ga, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that data from the Company’s OASIS Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) will be presented at the following medical meetings in February 2023: Conference:Angiogenesis, Exudation, and Degeneration 2023 – Virtual EditionPresentat

  • GlobeNewswire

    Clearside Biomedical Announces Leadership Team Update

    ALPHARETTA, Ga., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023. In his new adviso

  • GlobeNewswire

    Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

    - Suprachoroidal CLS-AX Resulted in Favorable Safety Data, Durability and Biologic Effect Over 6 Months in Treatment-Experienced Anti-VEGF Sub-Responders - - 67% of Extension Study Participants Went at Least 6 Months Without Needing Additional Treatment - - Extension Participants Experienced a 77 - 85% Reduction in Treatment Burden Over 6 Months - - Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Mark R. Barakat, M.D. - ALPHARETTA, Ga., Fe

  • GlobeNewswire

    Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

    ALPHARETTA, Ga., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in the following conferences in November and December 2022: BTIG Ophthalmology DayFireside ChatTuesday, November 29, 2022 at 10:30 a.m. ET Piper Sandler 34th Annual Healthcare ConferenceCorporate PresentationThursday, Decemb

  • GlobeNewswire

    Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

    ALPHARETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on Wed

  • GlobeNewswire

    Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

    - Favorable Safety Results, Durability and Biologic Effect Observed in Cohorts 3 and 4 of CLS-AX OASIS Phase 1/2a Trial - - Recent Positive Data Presentations Highlight the Potential Safety, Efficacy and Durability Benefits of Suprachoroidal Administration of Small Molecule Suspensions - - Management to Host Webcast and Conference Call on OASIS Data Today at 8:30 A.M. ET - ALPHARETTA, Ga., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company rev

  • GlobeNewswire

    Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients

    OASIS Demographics and Wet AMD History OASIS Demographics and Wet AMD History - Primary Safety Endpoint Achieved at all Timepoints with All Doses Well-Tolerated and No Treatment Related or Serious Adverse Events - - Cohorts 3 and 4 Demonstrated Promising Signs of Durability, Biologic Effect, and a Meaningful Reduction in Treatment Burden - - Final 6-Month Data from Extension Study Expected in Q1 2023 - - Expect to Initiate Phase 2 Clinical Trial in Q1 2023 - - Webcast and Conference Call Today a

  • GlobeNewswire

    Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

    Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D.ALPHARETTA, Ga., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company will host a conference call on Wednesday, November 9, 2022 at 8:30 a.m. Eastern Time to re

  • GlobeNewswire

    Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

    ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2022 financial results will be reported on Wednesday, November 9, 2022 before the open of the financial markets. Management will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the results and provide a corpora

  • GlobeNewswire

    Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform

    - Favorable Safety Profiles and Encouraging Efficacy Data Reported in Clinical Trials in the Suprachoroidal Space (SCS®) Across Multiple Therapeutic Areas using Clearside’s SCS Microinjector® - - SCS Microinjector® Featured in Multiple Oral and Poster Presentations at Recent American Academy of Ophthalmology (AAO) 2022 Annual Meeting - ALPHARETTA, Ga., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies

  • GlobeNewswire

    Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

    CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022ALPHARETTA, Ga., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer, will present a corporate overview at the Eyecelerator conference on September 29, 20

  • GlobeNewswire

    Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022

    ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview and participate in an industry panel virtually during the Ophthalmology Futures Retina Forum 2022 on August 31, 2022. Dr. Ciulla will be a

  • GlobeNewswire

    Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

    - CLS-AX OASIS Phase 1/2a Trial Data from Cohorts 3 & 4 Expected in November 2022 - - Non-Dilutive Financing Agreement with HealthCare Royalty Supports Progression of CLS-AX Clinical Program - - Management to Host Webcast and Conference Call Today at 8:30 A.M. ET - ALPHARETTA, Ga., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today r